Welcome to our dedicated page for Disc Medicine SEC filings (Ticker: IRON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Disc Medicine, Inc. (NASDAQ: IRON) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its clinical-stage biopharmaceutical business focused on serious hematologic diseases. These SEC filings cover financial results, capital-raising transactions, regulatory milestones, and key corporate events related to the company’s investigational programs in red blood cell biology, heme biosynthesis, and iron homeostasis.
Among the most frequently referenced documents are current reports on Form 8-K, where Disc Medicine discloses material events such as quarterly financial results, public offerings of common stock and pre-funded warrants, and significant regulatory developments. For example, the company has used 8-K filings to report a Commissioner’s National Priority Voucher from the U.S. Food and Drug Administration for bitopertin in erythropoietic protoporphyria, the submission of a New Drug Application under the accelerated approval pathway, and the terms of an underwriting agreement for an upsized public offering intended to support operations and development plans.
Investors also look to Disc Medicine’s periodic reports on Forms 10-K and 10-Q for comprehensive discussions of its pipeline, including bitopertin, DISC-0974, and DISC-3405, as well as risk factors and management’s analysis of financial condition. Filings may describe clinical trial status, patent coverage such as composition of matter protection for DISC-0974, and the company’s expectations regarding cash runway based on existing cash, cash equivalents, marketable securities, and offering proceeds.
On this page, users can access Disc Medicine’s SEC filings as they are made available through EDGAR. AI-powered tools can help summarize lengthy documents, highlight key sections on topics such as clinical development, financing terms, and forward-looking statements, and make it easier to understand how individual filings relate to the company’s broader strategy and risk profile. Forms 10-K, 10-Q, and 8-K, along with exhibits, provide the primary regulatory record for IRON and are central to in-depth fundamental research.
Disc Medicine (IRON) entered an Underwriting Agreement for an underwritten offering. The Company sold 2,619,049 shares of common stock at $84.00 and, in lieu of common to certain investors, pre-funded warrants for 59,523 shares at $83.9999. A selling stockholder sold 297,619 shares at $84.00, and the underwriters exercised in full a 30‑day option to buy an additional 446,428 shares from the selling stockholder.
Net proceeds to the Company are expected to be approximately $210.9 million after underwriting discounts and estimated expenses. The Company will receive nominal proceeds, if any, from pre-funded warrant exercises and no proceeds from the selling stockholder’s sales. Management stated that existing cash, cash equivalents and marketable securities plus these proceeds are expected to fund operations into 2029. Closing is expected on October 22, 2025.
Each pre-funded warrant is immediately exercisable at $0.0001 per share (cash or cashless), subject to an ownership cap up to 24.99%, adjustable with notice and HSR Act thresholds where applicable. The pre-funded warrants will not be listed on Nasdaq.
Disc Medicine (IRON) launched a combined primary and secondary offering of 2,619,049 shares of common stock and 59,523 pre-funded warrants, plus 297,619 shares offered by a selling stockholder. The offering priced at $84.00 per share and $83.9999 per pre-funded warrant.
Cash flows: Gross proceeds to the company are $211,500,039 before expenses, while the selling stockholder will receive $23,499,996; the company will not receive proceeds from the selling stockholder’s sales. Underwriting discounts and commissions total $15,000,003. The selling stockholder granted underwriters a 30‑day option to purchase up to an additional 446,428 shares at the public offering price, less underwriting discounts.
Warrants: The pre-funded warrants carry a $0.0001 per share exercise price, do not expire, and are exercisable after issuance, subject to ownership limits and, in some cases, HSR Act clearance. The company estimates net proceeds of approximately $210.9 million and plans to use them to support potential commercialization of bitopertin for EPP/XLP, advance R&D, and for general corporate purposes. As context, cash, cash equivalents and marketable securities were approximately $615.9 million as of September 30, 2025.
Disc Medicine (IRON) launched a mixed offering via a preliminary prospectus supplement: a $200,000,000 primary offering of common stock (and, at certain investors’ election, pre-funded warrants) and a $20,000,000 secondary offering by a selling stockholder. The selling stockholder granted underwriters a 30‑day option to purchase up to an additional $33.0 million of shares. The company’s stock trades on Nasdaq Global Market as IRON.
Pre‑funded warrants carry a $0.0001 exercise price, do not expire, and are exercisable subject to ownership limits (including 4.99%, 9.99%, 19.99% or up to 24.99%) and, in some cases, HSR Act clearance. There is no exchange listing for the pre‑funded warrants.
The company will receive proceeds only from the primary portion; it will not receive proceeds from the selling stockholder’s sales. Disc plans to use proceeds to support potential commercialization of bitopertin for EPP and XLP, fund R&D across its pipeline, and for general corporate purposes. Shares outstanding were 34,694,882 as of June 30, 2025. Preliminary cash, cash equivalents and marketable securities were approximately $615.9 million as of September 30, 2025.
Disc Medicine (IRON) furnished an update stating preliminary, unaudited cash, cash equivalents and marketable securities of approximately $615.9 million as of September 30, 2025. The company noted this figure is subject to change upon completion of quarter-end closing procedures and has not been audited or reviewed.
Disc also furnished a press release and filed an updated investor presentation highlighting its hematology portfolio and near‑term objectives, including programs bitopertin (GlyT1 inhibitor), DISC‑0974 (anti‑HJV; hepcidin suppression) and DISC‑3405 (anti‑TMPRSS6; hepcidin induction). The 8‑K materials under Items 2.02 and 7.01 were furnished, not filed.
Disc Medicine (IRON) director reported open‑market sales of common stock on 10/15/2025–10/17/2025. Transactions were executed in multiple tranches at weighted‑average prices, including ranges from $76.75–$77.60 and up to $92.15.
Following the sales, indirect holdings reported were 442,036 shares held by Atlas Venture Opportunity Fund I, LP; 385,549 shares held by Atlas Venture Opportunity Fund II, LP; and 51,000 shares held by Atlas Venture Fund XII, L.P. The reporting person is a member of the respective general partners and disclaims beneficial ownership beyond any pecuniary interest.
Disc Medicine (IRON) reported receiving a Commissioner’s National Priority Voucher (CNPV) from the U.S. FDA for bitopertin in erythropoietic protoporphyria (EPP), including X‑linked protoporphyria. The company previously submitted a New Drug Application in September 2025 for patients aged 12 and older under the FDA’s accelerated approval pathway.
The CNPV program, announced in June 2025, is intended to speed development and review of drugs tied to U.S. national health priorities. A CNPV provides benefits such as enhanced communications and rolling review, with the opportunity to reduce application review times to one to two months. This update highlights a potential pathway for a shortened FDA review of bitopertin after the NDA submission.
Director Kevin Bitterman reported a series of open-market sales of Disc Medicine, Inc. common stock executed on
Form 144 notice indicates an intended sale of 71,961 shares of common stock by an affiliate, to be executed through Merrill Lynch on
Disc Medicine, Inc. (IRON) notice reports a proposed sale of 18,039 common shares with an aggregate market value of
FAQ
What is the current stock price of Disc Medicine (IRON)?
What is the market cap of Disc Medicine (IRON)?
